Loading...
Docoh

AMGEN (AMGN)

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Company profile

Ticker
AMGN
Exchange
Website
CEO
Robert Bradway
Employees
Incorporated
Location
Fiscal year end
Former names
AMGEN
SEC CIK
Subsidiaries
Amgen (Europe) GmbH • Amgen Canada Inc. • Amgen Fremont Inc. • Amgen Global Finance B.V. • Amgen GmbH • Amgen Ilaç Ticaret Limited • Amgen K-A, Inc. • Amgen Manufacturing, Limited • Amgen Research (Munich) GmbH • Amgen Rockville, Inc. ...
IRS number
953540776

AMGN stock data

Calendar

4 Aug 22
9 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 5.2B 5.2B 5.2B 5.2B 5.2B 5.2B
Cash burn (monthly) 441.67M 118.92M (no burn) (no burn) (no burn) (no burn)
Cash used (since last report) 591.96M 159.38M n/a n/a n/a n/a
Cash remaining 4.61B 5.04B n/a n/a n/a n/a
Runway (months of cash) 10.4 42.4 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
31 Jul 22 Nancy A. Grygiel Common Stock Payment of exercise Dispose F No No 247.47 1,229 304.14K 13,728
31 Jul 22 Rachna Khosla Common Stock Payment of exercise Dispose F No No 247.47 217 53.7K 7,158
23 May 22 Williams R Sanders Common Stock Sell Dispose S No Yes 250 600 150K 5,501
17 May 22 Austin Wanda M Common Stock Grant Acquire A No No 0 855 0 4,886
78.4% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 2258 2229 +1.3%
Opened positions 172 297 -42.1%
Closed positions 143 155 -7.7%
Increased positions 946 846 +11.8%
Reduced positions 804 829 -3.0%
13F shares Current Prev Q Change
Total value 100.77B 94.99B +6.1%
Total shares 418.74M 422.56M -0.9%
Total puts 7.53M 3.96M +89.9%
Total calls 7.01M 3.88M +80.8%
Total put/call ratio 1.1 1.0 +5.0%
Largest owners Shares Value Change
BLK Blackrock 50.03M $12.1B -0.0%
Vanguard 47.33M $11.45B +1.4%
STT State Street 30.5M $7.38B +1.2%
Capital Research Global Investors 18.43M $4.46B -16.8%
Primecap Management 15.73M $3.8B -0.3%
MS Morgan Stanley 14.43M $3.49B +49.3%
Geode Capital Management 10.8M $2.61B +5.6%
Charles Schwab Investment Management 8.82M $2.13B +1.1%
NTRS Northern Trust 7.63M $1.85B -0.6%
WFC Wells Fargo & Co. 7.61M $1.84B +14.2%
Largest transactions Shares Bought/sold Change
Norges Bank 0 -5.06M EXIT
MS Morgan Stanley 14.43M +4.77M +49.3%
Capital Research Global Investors 18.43M -3.73M -16.8%
JPM JPMorgan Chase & Co. 5.61M +2.02M +56.1%
Capital International Investors 634.99K -1.95M -75.5%
BCS Barclays 1.26M -1.77M -58.3%
CFS Investment Advisory Services 1.27M +1.27M +24077.4%
BAC Bank Of America 7.19M +1.25M +21.1%
GS Goldman Sachs 2.56M -1.04M -28.8%
Healthcare Of Ontario Pension Plan Trust Fund 1.24K -958.25K -99.9%

Financial report summary

?
Management Discussion
  • Future sales of our products will depend in part on the factors discussed below and in the following sections of this report: (i) Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Overview, and Selected Financial Information; and (ii) Part II, Item 1A. Risk Factors, and in the following sections of our Annual Report on Form 10-K for the year ended December 31, 2021: (i) Part I, Item 1. Business—Marketing, Distribution and Selected Marketed Products; (ii) Part I, Item 1A. Risk Factors; and (iii) Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Overview, and Results of Operations—Product Sales, as well as in our Quarterly Report on Form 10-Q for the period ended March 31, 2022: (i) Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations—Product Sales; and (ii) Part II, Item 1A. Risk Factors.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: abandoning, AbbVie, adapted, added, adding, adjunctive, Advantage, Alzheimer, ANCA, argued, ASCVD, AVSOLA, awaiting, ballot, benchmark, Bergamo, biennial, body, broader, burden, burdensome, ceiling, certainty, ChemoCentryx, chosen, classified, coinsurance, complaint, component, constitutionality, contravention, Corlanor, CVS, cytoplasmic, de, deeper, discarded, divert, divestiture, dose, downstream, Dusseldorf, EIS, evolution, facto, familial, Finansal, Florida, formulary, Gensenta, Hampshire, HoFH, hypercholesterolemia, IMLYGIC, impede, improperly, inadequately, incremental, inflammatory, inhaled, inhibitor, inquiry, intensified, interference, interfering, interlocutory, IRP, jeopardize, la, launched, lawsuit, leverage, lieu, list, listed, losing, Maine, maintenance, marketplace, Mexico, nondeductible, nonstrategic, older, olpasiran, oppose, Orange, Oregon, outlined, permission, placement, plc, pleading, prejudice, pressure, pretax, proliferation, proportion, prostate, receptor, recommended, refine, refuse, repeal, restructuring, RIABNI, RNA, role, Sanayi, SAS, saving, siRNA, small, sought, standing, subcutaneously, suit, Ticaret, timeframe, top, topline, translation, Turkey, Turkish, unanticipated, unfair, unilaterally, upheld, usage, ve, Vermont, waived, Washington, week, withholding
Removed: al, amplify, build, collection, conduct, continuously, cybersecurity, decision, duration, EBITDA, emerging, evolving, home, Hospira, infection, inter, internationally, interrupted, iv, local, meaningful, oral, precipitate, privacy, protect, protection, referencing, relating, reliance, sell, spread, stemming, submit, succeed, transmission, vaccination, vulnerable, wide

Patents

Utility
CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
9 Aug 22
Inventors: Michael D. Bartberger, Hilary Plake Beck, Michael R. Degraffenreid, Brian M. Fox, Felix Gonzalez Lopez De Turiso, Lisa D. Julian, Frank Kayser, Julio C. Medina, Steven H. Olson, Yosup Rew, Philip M. Roveto, Daqing Sun, Xuelei Yan
Utility
Capture purification processes for proteins expressed in a non-mammalian system
9 Aug 22
Methods of purifying proteins expressed in non-mammalian expression systems in a non-native soluble form directly from cell lysate are disclosed.
Utility
Erenumab compositions and uses thereof
9 Aug 22
The present invention relates to compositions comprising erenumab and one or more erenumab variants, including isomerization variants, deamidation variants, acidic variants, and HMW species.
Utility
Vectors and Expression Systems for Producing Recombinant Proteins
4 Aug 22
Inventions disclosed herein relates to vectors and expression systems for producing heteromeric recombinant proteins such as monoclonal antibodies.
Utility
Solid State Forms
28 Jul 22
The present invention provides a crystalline form and stable salts of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1- piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several hydrochloride salt forms, phosphate salt form, mesylate salt form, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.